Vedanta : BALCO Medical Centre Bags Prestigious Cancer Grand Challenges Award, a First for India

Vedanta's BALCO Medical Centre Bags Prestigious Cancer Grand

Challenges Award, a First for India

• First Indian co-researchers team to receive $25 Million Cancer Grand Challenges award
• Esteemed award granted by Cancer Grand Challenges - a global research initiative co-founded by Cancer Research UK and National Cancer Institute US, two of the largest global funders of cancer research
• BMC is a state-of-the-art oncology institution serving a patient base of 35,000 in Central India

New Delhi, 6 March 2024: Vedanta's BALCO Medical Centre (BMC), an emerging leader in India's oncology space, has achieved a historic milestone by becoming the first Indian co-researchers in a team to receive the prestigious Cancer Grand Challenges Award. This recognition, with a substantial $25 million grant for cancer research, underscores BMC's position as a pioneering institution in India's oncology landscape. The recipient team PROSPECT, comprising of clinicians, advocates, and scientists from BALCO Medical Centre and other esteemed institutions around the world, will be addressing the critical issue of early-onset cancers challenge.

Ms. Jyoti Agarwal, Chairperson, Vedanta Medical Research Foundation, expressed her gratitude, stating, "We are honoured to have been chosen for this prestigious award, which significantly advances the battle against cancer. Over the past six years, at BMC, our leaders, employees, and stakeholders have worked tirelessly to ensure that we have access to the best technologies, and that our patients and communities feel safe and confident. With this support from Cancer Grand Challenges, our efforts are not only continued but also strengthened. With collaborative efforts, I am confident that we can positively contribute to the overall healthcare landscape."

Team PROSPECT is one of five global teams being funded this year by Cancer Grand Challenges, which was founded in 2020 by Cancer Research UK and the National Cancer Institute US, to invite diverse world-class research teams to come together, think differently and take on some of cancer's toughest challenges. The teams will be funded by Cancer Research UK, the National Cancer Institute, the Bowelbabe Fund for Cancer Research UK and Institute National Du Cancer through Cancer Grand Challenges with a total investment of $125m to tackle some of the toughest challenges in cancer research.

"Together with our network of visionary partners and research leaders, Cancer Grand Challenges unites the world's brightest minds across boundaries and disciplines and aims to overcome cancer's toughest problems," said Dr. David Scott, Director of Cancer Grand Challenges. "With this investment, our largest to date, we continue to grow our global research community, and fund new teams that have the potential to surface discoveries that could positively impact cancer outcomes."

Vedanta's BALCO Medical Centre, a state-of-the-art tertiary care Oncology facility in Central India, has been at the forefront of cancer care, providing multidisciplinary treatment and support. The

Sensitivity: Internal (C3)

institution is recognized as a referral centre for advanced radiation therapy, brachytherapy, nuclear medicine, surgeries, chemotherapy, and many more. Since inception in March 2018, BMC has treated more than 35,000 patients. Additionally, the institution has received many certifications and accreditations including LEED certification, NABH, FSSAI, NABL, Nursing Excellence, CAHO certifications. This significant grant underscores BMC's commitment to pioneering research and delivering innovative solutions to address critical healthcare challenges in India.

Dr. Bhawna Sirohi, Medical Director at Vedanta Medical Research Foundation (BALCO Medical

Centre) and the lead principal investigator for PROSPECT-India study, says "The worrisome increase in colorectal cancers stresses the importance of early detection and lifestyle choices for prevention. There's a dire need for cancer screening in high-riskareas to facilitate early diagnosis and prompt treatment, especially with the shifting demographics towards a younger population. This grant will speed up global cancer research, focusing on understanding the reasons behind the rise in early-onsetcolorectal cancer and strategies for prevention".

Early-onset colorectal cancer (EOCRC) is an important emerging global problem among individuals younger than 50 years. Team PROSPECT aims to address this by understanding the pathways, risk factors and molecules involved in its development. The team's vision is to understand and ultimately try to reverse the network of causal factors throughout the life course that disrupts normal biological processes to promote EOCRC. The team will employ a disruptive, transdisciplinary approach spanning cells, individuals and populations to uncover the mechanisms linking lifetime exposures to early-onset colorectal cancer, and test new strategies to combat this cancer type.

Currently, Cancer Grand Challenges brings together 1,200 researchers and 16 teams from across the world to take on 13 challenges. The spirit of giving back is part of the Vedanta's core values. This achievement brings the company closer to fulfilling the vision of contributing to the community and making a lasting impact on society.

Sensitivity: Internal (C3)

About Vedanta Limited

Vedanta Limited ("Vedanta"), a subsidiary of Vedanta Resources Limited, is one of the world's leading natural resources companies spanning across India, South Africa, Namibia, Liberia, UAE, Korea, Taiwan and Japan with significant operations in Oil & Gas, Zinc, Lead, Silver, Copper, Iron Ore, Steel, Nickel, Aluminium, Power & Glass Substrate and foraying into semiconductors and display glass. For two decades, Vedanta has been contributing significantly to nation building. Governance and sustainable development are at the core of Vedanta's strategy, with a strong focus on health, safety, and environment. Vedanta has put in place a comprehensive framework to be the ESG leader in the natural resources sector, is committed to reducing carbon emissions to net zero by 2050 or sooner and aims to spend $5 billion over the next 10 years to accelerate this transition. Giving back is in the DNA of Vedanta, which is focused on enhancing the lives of local communities. Anil Agarwal Foundation, the umbrella entity for Vedanta's social initiatives, has pledged Rs 5000 crore over the next five years on various social impact programs and its flagship project, Nand Ghar is setting up model anganwadis across India. Vedanta Ltd. has been listed in Dow Jones Sustainability World Index 2022, conferred Golden Peacock Award for excellence in Corporate Governance 2022 and certified as a Great Place to Work 2023. Vedanta Limited is listed on the Bombay Stock Exchange and the National Stock Exchange.

For more information, please visit www.vedantalimited.com

For any media queries, please contact:

Ms. Ritu Jhingon, Group Director - Communications, [e-mail]

Mr. Mukul Chhatwal, Group Head - PR & Media Relations, [e-mail]

About BALCO Medical Centre (BMC)

BALCO Medical Centre (BMC) is a 170-bed,state-of-the-art tertiary care Oncology facility in Naya Raipur. It is the flagship initiative of Vedanta Medical Research Foundation (VMRF), a non-profit organization by Vedanta Resources and Bharat Aluminium Company Ltd. (BALCO). BMC is emerging as a national leader in India's oncology space, providing comprehensive medical, surgical, radiation, haematological, BMT, and palliative care services. Although located in Naya Raipur, Chhattisgarh, it is rapidly becoming a preferred center for cancer treatment for people from Odisha, Madhya Pradesh, Jharkhand, Maharashtra, Andhra Pradesh.

For more information, visit www.balcomedicalcentre.com

For further information, please contact:

Mr. Vipendra Singh Rajput - Public Relations Officer, [e-mail] Medical Centre

[phone]

About Cancer Grand Challenges

Co-founded in 2020 by two of the largest funders of cancer research in the world: Cancer Research UK and the National Cancer Institute, Cancer Grand Challenges supports a global community of diverse, world-class research teams to come together, think differently and take on some of cancer's toughest challenges. These are the obstacles that continue to impede progress and no one scientist, institution or country will be able to solve them alone. With awards of up to $25M, Cancer Grand Challenges teams are empowered to rise above

Sensitivity: Internal (C3)

the traditional boundaries of geography and discipline to make the progress against cancer we urgently need.

For further information, please contact:[e-mail]

Sensitivity: Internal (C3)